The Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?

Basit Öğe Kaydı
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorAraz, Murat
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorSezgin, Yasin
dc.contributor.authorEryılmaz, Melek Karakurt
dc.contributor.authorKaraağaç, Mustafa
dc.date.accessioned2024-04-24T19:11:50Z
dc.date.available2024-04-24T19:11:50Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: Pazopanib is an orally administered drug and has approval for the treatment of advanced Soft TissueSarcomas (aSTS). The absorption of pazopanib is pH-dependent. Acid-Reducing drugs such as proton pump inhibitors(PPI) may reduce the bioavailability of pazopanib. The primary purpose of this study was to assess whether the use ofconcomitant PPI and pazopanib had negative effects on survival outcomes.Methods: In this retrospective cross-sectional study, age ?18 years, having histologically proven STS, receiving pazopanibat least one day, and availability of information about the use of PPI during pazopanib treatment were the inclusioncriteria. Patients with adipocytic sarcoma were excluded.Results: A total of 46 eligible patients were assessed in this study. Thirty-one patients used concomitant PPI andpazopanib, 17 of them frequently used PPI, and the others occasionally. Fifteen patients never used concomitant PPI andpazopanib. The median progression-free survival (PFS) was 2.76 months, and the median overall survival (OS) was7.39?months for patients who never used concomitant PPI and pazopanib. Also, the median PFS was 5.22 months, and themedian OS was 14.52?months for patients who used concomitant PPI and pazopanib. In univariate analysis; usingconcomitant PPI (p=0.049) and primarily uterine located tumors (p=0.038) were significant parameters for PFS. Inmultivariate logistic regression analysis; both of using concomitant PPI (Wald=6.02; p=0.014) and primarily uterinelocated tumors (Wald=5.69; p=0.017) retained their association with longer PFS. No parameter was significant for OS.Conclusions: We showed that the use of concomitant PPI and pazopanib was associated with improved PFS. These resultsmay help guide clinicians and researchers for allowing patients co-administrating PPI and pazopanib, especially whentreating or investigating patients with dyspeptic symptoms.en_US
dc.identifier.doi10.5798/dicletip.706025
dc.identifier.endpage88en_US
dc.identifier.issn1300-2945
dc.identifier.issn1308-9889
dc.identifier.issue1en_US
dc.identifier.startpage82en_US
dc.identifier.trdizinid370621
dc.identifier.urihttps://doi.org/10.5798/dicletip.706025
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/370621
dc.identifier.urihttps://hdl.handle.net/11468/28218
dc.identifier.volume47en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofDicle Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleThe Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?en_US
dc.titleThe Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Dicle Tıp Dergisi